Number of megarounds drops 38% in first half as biotechs struggle against worsening slump
Even biotech’s “haves” are struggling.
The sector’s fraught funding environment has been in a slump going on three years, and it’s created a world of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
